Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Capital Expenditures (2016 - 2024)

Moleculin Biotech's Capital Expenditures history spans 9 years, with the latest figure at $13000.0 for Q2 2024.

  • Quarterly results put Capital Expenditures at $13000.0 for Q2 2024, down 13.33% from a year ago — trailing twelve months through Mar 2025 was $13000.0 (down 89.52% YoY), and the annual figure for FY2024 was $13000.0, down 89.52%.
  • Capital Expenditures for Q2 2024 was $13000.0 at Moleculin Biotech, down from $81000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $296000.0 in Q3 2020 to a low of -$316000.0 in Q4 2020.
  • The 5-year median for Capital Expenditures is $18000.0 (2020), against an average of $20272.7.
  • Peak annual rise in Capital Expenditures hit 1309.52% in 2020, while the deepest fall reached 3260.0% in 2020.
  • Year by year, Capital Expenditures stood at -$316000.0 in 2020, then surged by 106.01% to $19000.0 in 2021, then skyrocketed by 221.05% to $61000.0 in 2022, then skyrocketed by 32.79% to $81000.0 in 2023, then crashed by 83.95% to $13000.0 in 2024.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $13000.0, $81000.0, and $28000.0 for Q2 2024, Q4 2023, and Q3 2023 respectively.